Status:
UNKNOWN
Can Contrast Enhanced Spectral Mammography (CESM) Reduce the Number of Benign Biopsies for Calcifications Without Negatively Impacting on Detection/Diagnosis of Clinically Significant Calcifications
Lead Sponsor:
The Leeds Teaching Hospitals NHS Trust
Conditions:
Mammography
Eligibility:
FEMALE
50-70 years
Phase:
NA
Brief Summary
Women who attend for their screening mammogram will be recalled if an abnormality is detected on the screening mammogram. Calcifications account for 20% of the women recalled to second stage screening...
Eligibility Criteria
Inclusion
- Recalled for second stage screening due to microcalcifications on the mammogram
- Renal function is within normal limits
- No known allergies to contrast
- Able to give informed consent
Exclusion
- Known allergy to contrast
- Renal impairment
- Unable to provide informed consent
- Having radioactive iodine treatment for hyperthyroidism
Key Trial Info
Start Date :
December 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 2 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT03857152
Start Date
December 3 2018
End Date
February 2 2021
Last Update
February 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS1 3HE,